Novo Nordisk A/S $NVO Shares Sold by QRG Capital Management Inc.

QRG Capital Management Inc. decreased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 44.4% in the third quarter, Holdings Channel.com reports. The institutional investor owned 129,331 shares of the company’s stock after selling 103,385 shares during the quarter. QRG Capital Management Inc.’s holdings in Novo Nordisk A/S were worth $7,177,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of NVO. True Wealth Design LLC grew its stake in Novo Nordisk A/S by 209.8% during the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after acquiring an additional 300 shares in the last quarter. NewSquare Capital LLC grew its position in shares of Novo Nordisk A/S by 174.1% in the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after purchasing an additional 282 shares in the last quarter. Mid American Wealth Advisory Group Inc. purchased a new stake in shares of Novo Nordisk A/S in the second quarter valued at approximately $37,000. Maseco LLP acquired a new stake in shares of Novo Nordisk A/S in the second quarter valued at approximately $39,000. Finally, Steigerwald Gordon & Koch Inc. acquired a new position in Novo Nordisk A/S during the third quarter worth $39,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $62.32 on Friday. The firm has a 50-day simple moving average of $50.85 and a two-hundred day simple moving average of $54.97. The stock has a market cap of $278.26 billion, a PE ratio of 18.12 and a beta of 0.66. Novo Nordisk A/S has a 1-year low of $43.08 and a 1-year high of $93.80. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.57.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. The firm had revenue of $11.79 billion during the quarter, compared to analysts’ expectations of $11.98 billion. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. As a group, analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Wall Street Analyst Weigh In

NVO has been the topic of several analyst reports. The Goldman Sachs Group reduced their price target on Novo Nordisk A/S from $60.00 to $54.00 and set a “buy” rating on the stock in a report on Friday, November 28th. Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, January 9th. CICC Research started coverage on shares of Novo Nordisk A/S in a report on Friday, January 9th. They issued an “outperform” rating and a $73.50 target price on the stock. BMO Capital Markets restated a “market perform” rating on shares of Novo Nordisk A/S in a report on Wednesday. Finally, Argus reiterated a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $56.21.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Early U.S. launch showed encouraging demand — oral Wegovy recorded 3,071 prescriptions in the first four days after launch, a datapoint traders flagged as a strong initial uptake. Read More.
• Positive Sentiment: Analyst notes described the rollout as a “solid start,” supporting upside expectations while emphasizing the need for more data to gauge sustained demand. Read More.
• Positive Sentiment: U.K. regulator approved a higher Wegovy dose (up to 7.2 mg weekly), expanding label flexibility and the addressable market for higher‑intensity treatment. Read More.
• Neutral Sentiment: Some analysts caution early prescription figures may not fully reflect long‑term demand or uptake dynamics; UBS warned initial data can be misleading even while it lifted its price target. Read More.
• Neutral Sentiment: High trading volume and elevated market attention increase short‑term volatility as investors parse launch metrics, regulation and competitor actions. Read More.
• Negative Sentiment: Legal risk: a compounding pharmacy has sued Novo (and Eli Lilly) over GLP‑1 access, alleging antitrust issues — a development prompting near‑term share pressure and regulatory/legal expense risk. Read More.
• Negative Sentiment: Valuation concerns persist: commentary argues Novo’s current valuation may not fully justify bullishness if growth or pricing faces headwinds, a viewpoint that can temper upside. Read More.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.